Updates for Cardio-Kidney Protective Effects by Angiotensin Receptor-Neprilysin Inhibitor: Requirement for Additional Evidence of Kidney Protection.

29 For patients with eGFR <60 mL/min/1.73 m 2 (N=2754), sacubitril/valsartan displayed a positive trend for both the prespecified kidney composite outcome and the new postanalysis kidney composite outcome, but it did not demonstrate a statistical advantage over enalapril for either outcome (HR, 0.64 [95% CI, 0.37–1.08]; HR, 0.64 [95% CI, 0.34–1.19], respectively). 29 There was also no difference

also in 11,005 other papers